0001104659-20-115697 Sample Contracts

EXCLUSIVE LICENSE AGREEMENT between EMORY UNIVERSITY, CHILDREN’S HEALTHCARE OF ATLANTA, INC., UAB RESEARCH FOUNDATION, and Incysus, LTD.
Exclusive License Agreement • October 16th, 2020 • In8bio, Inc. • Biological products, (no disgnostic substances) • Georgia
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Second Amendment to Exclusive License Agreement between Emory University (“Emory”), Children’s Healthcare of Atlanta, Inc. (“CHOA”), The UAB Research Foundation (“UABRF”) and Incysus , Ltd.
Exclusive License Agreement • October 16th, 2020 • In8bio, Inc. • Biological products, (no disgnostic substances)

This Second Amendment to Exclusive License Agreement (this “Second Amendment”) is made effective as of the date of the last signature of the Parties (as evidenced below their signatures on the signature page) (the “Second Amendment Effective Date”) by and between Emory University, Children’s Healthcare of Atlanta, Inc., The UAB Research Foundation (hereinafter together the “LICENSOR”) and Incysus Therapeutics, Inc. (“COMPANY”). COMPANY and Licensor may be each individually referred to as a party and collectively, the parties (“Party” or “Parties”).

Sample 1Sample 2
Exclusive License Agreement Between The UAB Research Foundation and Incysus, Ltd. March 10, 2016
Exclusive License Agreement • October 16th, 2020 • In8bio, Inc. • Biological products, (no disgnostic substances) • Alabama

This exclusive license agreement (this “Agreement”) is made and is effective as of March 10th, 2016 (the “Effective Date”) between The UAB Research Foundation (“UABRF”), a non-profit 501(c)(3) corporation incorporated in the State of Alabama with its principal place of operations at 701 20th Street South, Birmingham, AL 35233 and Incysus, Ltd. (the “Licensee”), an entity incorporated in Bermuda, with its principal place of operations at Clarendon House 2 Church Street Hamilton HM 11, Bermuda.

Sample 1Sample 2
Contract
Warrant Agreement • October 16th, 2020 • In8bio, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

Sample 1
First Amendment to Exclusive License Agreement between Emory University (“Emory”), Children’s Healthcare of Atlanta, Inc. (“CHOA”), The UAB Research Foundation (“UABRF”) and Incysus, Ltd.
Exclusive License Agreement • October 16th, 2020 • In8bio, Inc. • Biological products, (no disgnostic substances)

This First Amendment to Exclusive License Agreement (this “First Amendment”) is made effective as of the date of the last signature of the Parties (as evidenced below their signatures on the signature page) (the “First Amendment Effective Date”) by and between Emory University, Children’s Healthcare of Atlanta, Inc., The UAB Research Foundation (hereinafter together the “LICENSOR”) and Incysus, Ltd. (“COMPANY”). COMPANY and Licensor may be each individually referred to as a party and collectively, the parties (“Party” or “Parties”).

Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!